Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry

Autor: Fox, KAA, Virdone, S, Bassand, J-P, Camm, AJ, Goto, S, Goldhaber, SZ, Haas, S, Kayani, G, Koretsune, Y, Misselwitz, F, Oh, S, Piccini, JP, Parkhomenko, A, Sawhney, JPS, Stepinska, J, Turpie, AGG, Verheugt, FWA, Kakkar, AK, GARFIELD-AF investigators

OBJECTIVE: In patients with newly diagnosed atrial fibrillation (AF), do baseline risk factors and stroke prevention strategies account for the geographically diverse outcomes. DESIGN: Global Anticoagulant Registry in the FIELD-Atrial Fibrillation is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::56f81169a3f834b48e89399d8144e73e
https://openaccess.sgul.ac.uk/id/eprint/114053/1/e049933.full.pdf

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

Autor: Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH, Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function.

Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of exces

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1299::7b86337b4b4ba0f093adc5fb9cb6ccd9
http://hdl.handle.net/10281/279854

Outcomes in newly diagnosed atrial fibrillation and history of acute coronary syndromes: insights from GARFIELD-AF

Autor: Verheugt, FW, Ambrosio, G, Atar, D, Bassand, J-P, Camm, AJ, Costabel, JP, Fitzmaurice, DA, Illingworth, L, Goldhaber, SZ, Goto, S, Haas, S, Jansky, P, Kayani, G, Stepinska, J, Turpie, AG, van Eickels, M, Kakkar, AK, GARFIELD-AF Investigators

BACKGROUND: Many patients with atrial fibrillation have concomitant coronary artery disease with or without acute coronary syndromes and are in the need of additional antithrombotic therapy. There are few data on the long-term clinical outcome of atr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::b177fae28897458e5c3c74c236024e75
https://openaccess.sgul.ac.uk/id/eprint/111045/1/1-s2.0-S0002934319305431-main.pdf

The Risk of Permanent Discontinuation of Oral Anticoagulation in Patients With Atrial Fibrillation: Data From the GARFIELD-AF Registry

Autor: Cools, F, Camm, AJ, Bassand, J-P, Verheugt, FWA, Yang, S, Tsiatis, AA, Fitzmaurice, DA, Goldhaber, SZ, Goto, S, Haas, S, Misselwitz, F, Turpie, AGG, Fox, KAA, Kakkar, AK

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::6fc0aa54f0f07f7e0e63fc115d0045b7

Extended use of dabigatran, warfarin, or placebo in venous thromboembolism

Autor: Schulman, S1, Kearon, C, Kakkar, AK, Schellong, S, Eriksson, H, Baanstra, D, Kvamme, AM, Friedman, J, Mismetti, P, Goldhaber, SZ, Schulman, S, Goldhaber, S, Kakkar A, DI MINNO, GIOVANNI

Publikováno v: New England journal of medicine, 368(8), 709-718. Massachussetts Medical Society
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2013, 368 (8), pp.709-18. ⟨10.1056/NEJMoa1113697⟩
Schulman, S, Kearon, C, Kakkar, A K, Schellong, S, Eriksson, H, Baanstra, D, Kvamme, A M, Friedman, J, Nurmohamed, M T, Mismetti, P & Goldhaber, S Z 2013, ' Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. ', New England Journal of Medicine, vol. 368, no. 8, pp. 709-718 . https://doi.org/10.1056/NEJMoa1113697
New England Journal of Medicine, 368(8), 709-718. Massachussetts Medical Society
Schulman, S, Kearon, C, Kakkar, A K, Schellong, S, Eriksson, H, Baanstra, D, Kvamme, A M, Friedman, J, Mismetti, P, Goldhaber, S Z & RE-MEDY Trial Investigators 2013, ' Extended use of dabigatran, warfarin, or placebo in venous thromboembolism ', The New England Journal of Medicine, vol. 368, no. 8, pp. 709-18 . https://doi.org/10.1056/NEJMoa1113697

International audience; BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism. METHODS: In two double-blind, randomized trials, we co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49c6d84e6bef3f708aafee8a518c7246
http://hdl.handle.net/10447/96631